



DIGITAL ACCESS TO SCHOLARSHIP AT HARVARD

Human β -Cell Proliferation and Intracellular Signaling: Driving in the Dark Without a Road Map

The Harvard community has made this article openly available.
[Please share](#) how this access benefits you. Your story matters.

Citation	Kulkarni, Rohit N., Ernesto-Bernal Mizrachi, Adolfo Garcia Ocana, and Andrew F. Stewart. 2012. "Human β -Cell Proliferation and Intracellular Signaling: Driving in the Dark Without a Road Map." <i>Diabetes</i> 61 (9): 2205-2213. doi:10.2337/db12-0018. http://dx.doi.org/10.2337/db12-0018 .
Published Version	doi:10.2337/db12-0018
Accessed	February 19, 2015 2:33:24 PM EST
Citable Link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:11877092
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

(Article begins on next page)

Human β -Cell Proliferation and Intracellular Signaling

Driving in the Dark Without a Road Map

Rohit N. Kulkarni,^{1,2} Ernesto-Bernal Mizrahi,³ Adolfo Garcia Ocana,⁴ and Andrew F. Stewart⁴

A major goal in diabetes research is to find ways to enhance the mass and function of insulin secreting β -cells in the endocrine pancreas to prevent and/or delay the onset or even reverse overt diabetes. In this *Perspectives in Diabetes* article, we highlight the contrast between the relatively large body of information that is available in regard to signaling pathways, proteins, and mechanisms that together provide a road map for efforts to regenerate β -cells in rodents versus the scant information in human β -cells. To reverse the state of ignorance regarding human β -cell signaling, we suggest a series of questions for consideration by the scientific community to construct a human β -cell proliferation road map. The hope is that the knowledge from the new studies will allow the community to move faster towards developing therapeutic approaches to enhance human β -cell mass in the long-term goal of preventing and/or curing type 1 and type 2 diabetes. *Diabetes* 61:2205–2213, 2012

THE CHALLENGE OF INDUCING HUMAN β -CELL REPLICATION

A principal goal of the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases, Juvenile Diabetes Research Foundation, American Diabetes Association, and their European and Asian equivalents is to develop viable therapeutic approaches to induce adult human β -cell replication/expansion for regeneration therapies in patients with type 1 diabetes and/or type 2 diabetes mellitus (T2DM). Unfortunately, all observers of adult human β -cell replication find that it is very limited ($\sim 0.2\%$ of β -cells/24 h) and poorly responsive or unresponsive to the many mitogens, growth factors, and nutrients that have been shown to induce expansion in rodent models. For example, glucagon-like peptide-1 (GLP-1) and its analog, exendin-4, hepatocyte growth factor (HGF), lactogens, insulin, IGF-I, and many other molecules have been shown to increase rat and mouse β -cell proliferation and mass expansion, but have shown limited effects in human β -cells.

SPECIES- AND AGE-RELATED FAILURE OF β -CELL REPLICATIVE CAPACITY

Some of this refractoriness to proliferation in both rodents and humans is age-related. For example, whereas β -cell replication is easy to induce using exendin-4 or partial pancreatectomy in young mice, it is markedly attenuated in older mice (1). Similarly, whereas β -cell replication has been difficult to induce in adult human β -cells, reports of human embryonic and neonatal β -cell proliferation do indicate that proliferation can occur in juvenile human β -cells (2,3). But even in this study, the proliferation is very limited ($\sim 2\text{--}4\%$ in embryonic human β -cells by Ki-67 staining) as compared with other fetal and adult tissues (e.g., spleen, bone marrow, gastrointestinal crypts, basal keratinocytes) where proliferation is often 10-fold higher.

In contrast, there are also clear species differences, because rodent β -cell models can display relatively large proliferative responses (e.g., 10–15%), whereas this type of proliferation is never seen in human β -cells under physiological conditions, even in embryonic life. Perhaps more germane to human diabetes, whatever the underlying reasons, these issues are a major hurdle to driving therapeutic human β -cell expansion, because the major source of human β -cells is adult cadaveric donors, and the major therapeutic target for expansion of endogenous human β -cells, at least initially, will be adults with type 1 diabetes mellitus. Thus, there is an urgent need to understand why adult β -cells are refractory to replication, and, at the end of this *Perspectives in Diabetes* article, we suggest a series of questions to be addressed by the scientific community to reverse this state of ignorance.

THE RODENT β -CELL RECEPTOR–NUTRIENT–SIGNALING–CELL-CYCLE PATHWAY ROAD MAP

In rodent β -cells, we have an impressive and expanding intracellular signaling road map, or “wiring diagram,” that reveals how proliferation normally occurs, how it intersects with downstream cell-cycle machinery, and how it can be manipulated for therapeutic purposes. Space prevents a detailed discussion of every pathway, but several oversimplified examples are shown in Figs. 1–3 and described briefly below.

SIGNALING PATHWAYS

Insulin receptor substrate/phosphatidylinositol-3 kinase/Akt signaling. Insulin and IGF-I constitute two primary members of the growth factor family for which receptors are expressed ubiquitously and mediate the growth and metabolic effects of the hormones in virtually all mammalian tissues. Insulin and IGF-I classically bind to

From ¹Islet Cell Biology and Regenerative Medicine, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts; the ²Department of Medicine, Harvard Medical School, Boston, Massachusetts; the ³Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan; and the ⁴Division of Endocrinology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Corresponding authors: Rohit N. Kulkarni, rohit.kulkarni@joslin.harvard.edu, and Andrew F. Stewart, stewarta@pitt.edu.

Received 16 January 2012 and accepted 25 April 2012.

DOI: 10.2337/db12-0018

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.




FIG. 1. A working model depicting some of the multiple signaling pathways that have been reported to modulate cell-cycle activation and/or proliferation in rodent β-cells. Note that although this model is reasonably robust, it is nonetheless preliminary and will require amendment and addition over time. The growth factors (insulin, IGF-I, HGF) and the incretin hormone GLP-1 are linked to the IRS/PI3K pathway, which in turn signals via PDK-1 to modulate Akt and FoxO1. Nutrients have also been reported to modulate PI3K, block AMP-activated protein kinase, and modulate mTORC1. PI3K activation following HGF binding to its tyrosine kinase receptor, c-Met, results in the production of phosphatidylinositol trisphosphate that directly binds to the pleckstrin homology domain of PDK-1. PDK-1 then attaches to the hydrophobic motif of PKCζ, phosphorylates Thr410, and exposes the kinase domain to autophosphorylation of Thr560, a phosphorylation required for full catalytic activity. PKCζ activation leads to inactivation of GSK3β and increased phosphorylation and activation of mTORC1. Activation of mTORC1 is required for PKCζ-mediated induction of rodent β-cell proliferation. Lactogen signaling is activated by the prolactin receptor and acts via Jak2/Stat5 and/or Jak2/Bcl6/menin and/or tryptophan hydroxylases, which generate serotonin. Serotonin is assumed to act via the *HTR2b* receptor to modulate intracellular calcium and PKC or PI3K members. The FoxO proteins, downstream targets of Akt, are reported to regulate the cell cycle, although it is unclear how this directly impacts β-cell cycle control. Transcriptional repression of cyclin D is required for FoxO-mediated inhibition of cell-cycle progression and transformation, and FoxO proteins have been reported to upregulate the transcription of p27Kip1. The phosphorylation of FoxO1 by Akt is reported to prevent the transcription factor Foxo2 from driving the expression of Pdx1, which mediates the proliferation/differentiation of β-cells in response to FoxO1 (90). Akt can also downregulate p21Cip1 activity indirectly through MDM2/p53. Insulin and IGF-I can also promote proliferation independently of the PI3K pathway by acting through proteins that act by extracellular signal-related kinase-dependent and -independent (Raf1) pathways. (A high-quality color representation of this figure is available in the online issue.)

their own receptors, but can also cross-react and activate common downstream proteins. Receptor activation transmits signals by phosphorylating insulin receptor substrates (IRS), including the four IRS proteins—Shc, Gab-1, focal adhesion kinase, and Cbl—and others, leading to activation of phosphatidylinositol-3 kinase (PI3K)/Akt (see below). Several recent reviews provide an excellent resource for interested readers (4,5). Mouse β-cells express both the insulin and IGF-I receptors, and most components of their signaling pathways. Recent studies on insulin receptor (IR) signaling in β-cells have provided cumulative evidence for an autocrine role of insulin on its own receptor. Two early mouse models that provided direct genetic evidence for a role for insulin/IGF-I signaling in the regulation of β-cell biology include the β-cell-specific knockout of the IR (βIRKO) (6) and the global knockout of IRS-2 (7). Both βIRKO and IRS2KO mice failed to maintain their β-cell mass and manifested a phenotype most resembling human T2DM. Following these two studies, multiple laboratories have reported the creation and characterization of transgenics/KOs complemented by in vitro and ex vivo approaches to indicate the significance of proteins in the insulin/IGF-I cascade for the regulation of β-cells (5).

Contrary to traditional thought, we and others have used genetic approaches to directly demonstrate that the insulin/IGF-1 signaling pathway is not critical for early development of β-cells (5,8). However, whereas both βIRKO and β-cell-specific IGF-1 receptor KO mice exhibit impaired glucose tolerance and secretory defects, only

βIRKO mice show an age-dependent decrease in β-cell mass and an increased susceptibility to develop overt diabetes, suggesting a dominant role for insulin signaling in the regulation of adult β-cell mass (9). It has been observed for several decades that mouse models of diabetes and obesity exhibit a remarkable ability to compensate for the increase in insulin demand in response to insulin resistance. One such model, the liver-specific IR KO mouse, develops severe insulin resistance and glucose intolerance, but the mice do not become overtly diabetic due, in part, to an ~30-fold increase in β-cell mass as a compensatory mechanism to counter the ambient insulin resistance (9,10).

The IRSs and Akt, important downstream signaling molecules in the IR/IGF-I receptor signaling pathway, have been reported to play a dominant role in β-cell growth. Indeed, global KO of IRS-1 in mice leads to postnatal growth retardation and hyperplastic and dysfunctional islets, but the mice do not develop overt diabetes due to β-cell compensation (11–13). In contrast, IRS-2 global KOs develop mild growth retardation and, depending on their genetic background, develop either mild glucose intolerance or β-cell hypoplasia and overt diabetes (7,14). β-cell-specific deletion of IRS-2 also leads to mild diabetes (15). Importantly, IRS-2 mediates the effects of the incretin hormone, GLP-1, to promote survival and/or proliferation of rodent β-cells (16). Thus, IRS-2 appears to be a positive regulator of β-cell compensation, whereas IRS-1 predominantly regulates insulin secretion.

A similar scenario is observed in the context of the Akt isoforms. Thus, global KOs for Akt2 develop overt diabetes largely due to insulin resistance in peripheral tissues and β -cell failure, despite islet hyperplasia and hyperinsulinemia (17,18). Transgenic mice expressing a kinase-dead mutant of Akt1 under control of the rat insulin I promoter showed increased susceptibility to diabetes following fat feeding (19). Islet hyperplasia, β -cell hypertrophy, and hyperinsulinemia are observed in β -cell-specific transgenic mice expressing constitutively active Akt1 (20,21). Akt regulates proliferation by modulation of multiple downstream targets including glycogen synthase kinase-3 (GSK3) (see below), FoxO1, and tuberous sclerosis proteins (TSC)/mammalian target of rapamycin (mTOR) among others. Recent experiments have also linked the cyclin/cyclin-dependent kinase (CDK) 4 complex to Akt in β -cell proliferation, showing that Akt1 upregulates cyclins D1 and D2, p21Cip1 levels (but not p27Kip1), and CDK4 activity (22). Collectively, these *in vivo* data suggest a dual role for the Akt in the regulation of β -cell mass. In addition to regulating proliferation, class Ia PI3K also modulates β -cell function by multiple mechanisms (23).

GSK3 and liver kinase B1 signaling. GSK3 is a ubiquitously expressed serine/threonine protein kinase originally identified as a regulator of glycogen metabolism. It is now well-established that GSK3 acts as a downstream regulatory switch for numerous signaling pathways and is involved in cell-cycle regulation and cell proliferation. There are two mammalian GSK3 isoforms encoded by distinct genes: GSK3 α and GSK3 β . Activated Akt phosphorylates and inactivates GSK3. GSK3 phosphorylation was observed in mice overexpressing a constitutively active form of Akt1 in β -cells (22), which correlated with an increase in cyclin D1 levels in islets, suggesting that GSK3 is an important negative regulator of β -cell cycle progression in mice. Indeed, a decrease in GSK3 β expression can correct diabetes in mouse models of insulin resistance (24,25). More recently, the GSK3 β / β -catenin/T-cell factor pathway has been shown to act in concert with cAMP-responsive element-binding protein (CREB) to downregulate cyclin D2 expression by phosphatase and tensin homolog (PTEN), suggesting a convergence of the PI3K/PTEN and Wnt pathways. Furthermore, phosphorylation and activation of TSC2 by GSK3 β inhibits mTOR signaling (26). However, whether this occurs in β -cells is unknown.

Another kinase that physically associates *in vivo* with GSK3 β is the tumor suppressor liver kinase B1 (LKB1). Loss of LKB1 in adult β -cells increases β -cell proliferation, size, and mass and enhances glucose tolerance in mice (27,28), suggesting that this kinase is a regulator of β -cell growth *in vivo* in rodents. LKB1 is also known to associate with protein kinase C ζ (PKC ζ), as described below. Whether there is any interaction among these three different kinases in the β -cell is currently unclear.

TSC, mTOR, S6 kinase, and 4E-BP1 signaling. mTOR is essential for cell growth and proliferation and is part of two mTOR complexes (mTORC), mTORC1 and 2 [recently reviewed (29)]. mTORC1 activity is negatively regulated by TSC1, TSC2, and the small G protein Rheb. TSC2 phosphorylation and inactivation by Akt and extracellular signal-related kinase, among other kinases, releases the inhibition of Rheb, leading to activation of mTOR (29). In contrast, phosphorylation and activation of TSC2 by several kinases inhibits mTOR signaling (29). mTORC1 constitutes the rapamycin-sensitive arm of mTOR signaling and

contains at least three proteins: raptor, mLst/G β L, and PRAS40 (29). This pathway integrates signals from growth factors and nutrients and controls growth (cell size), proliferation (cell number), and metabolism by directly modulating 4E-BP and S6 kinases (S6K) and by indirectly attenuating Akt signaling via an mTORC1/S6K-mediated negative-feedback loop on IRS signaling. S6K phosphorylates downstream substrates, such as ribosomal S6 protein and eukaryotic translation initiation factor 4B, to promote mRNA translation and synthesis of ribosomes. Phosphorylation of 4E-BPs triggers their release from eukaryotic translation initiation factor 4E and initiates cap-dependent translation. Thus, mTORC1 substrates regulate cell growth, proliferation, and mRNA translation initiation and progression, thereby controlling the rate of protein synthesis.

As relates to β -cells, evidence from mouse genetic models demonstrates that mice with conditional deletion of TSC2 (leading to mTORC1 activation) in β -cells exhibit increases in β -cell mass, proliferation, and cell size (30). Separate studies demonstrated that conditional deletion of TSC2 or TSC1 in β -cells causes a similar phenotype, but these mice developed diabetes and β -cell failure after 40 weeks (31,32). Further confirmation of the effect of mTORC1 activation to increase β -cell mass comes from mice overexpressing Rheb in β -cells (33). However, proliferation in β -cells with mTORC1 activation has not been demonstrated in all studies: thus, precisely how mTORC1 acting upon 4E-BPs and S6K modulates β -cell mass, proliferation, and function is unclear. Evidence for a role of S6K in β -cell proliferation was demonstrated in mice with activation of Akt signaling in an S6K1-deficient background (34). However, S6K1 gain of function by transgenic overexpression failed to induce proliferation, in part due to negative feedback on IRS-1 and -2 signaling (35). The importance of 4E-BPs on regulation of β -cell proliferation is hard to decipher at present because of alterations in insulin sensitivity in global KO models.

Further evidence for a role of mTORC1 in β -cell proliferation comes from studies with its inhibitor, rapamycin. These studies demonstrate that: 1) rapamycin treatment blocks β -cell expansion, cell size, and proliferation induced by activation of Akt in β -cells (36). The inhibition of β -cell proliferation by rapamycin results from decreases in cyclin D2 and D3 and in cyclin-dependent kinase (cdk) 4 activity. 2) Rapamycin treatment results in reduced proliferation in β -cells in pregnant mice and causes antiproliferative effects on transplanted rat β -cells *in vivo* (37,38). 3) Rapamycin also attenuates β -cell expansion in a model of insulin resistance and β -cell regeneration (39,40) and reduces proliferation of rodent islets *in vitro* (41). These studies support the concept that mTORC1 plays an important role in the regulation of β -cell mass and cell cycle and can mediate adaptation of β -cells to insulin resistance.

The mTORC2 complex, containing rictor, mSin, and protor, is insensitive to rapamycin. This complex phosphorylates Akt on Ser473, suggesting that this pathway indirectly could be linked to proliferation. However, the only evidence for a role for mTORC2 in β -cells comes from mice with conditional deletion of rictor in β -cells (42). These mice exhibit mild hyperglycemia resulting, in part, from decreased β -cell proliferation, mass, and insulin secretion.

Other pathways: PKC ζ signaling. PKC ζ is a member of the atypical PKC subfamily activated by PI3K/3'-PI-dependent protein kinase-1 (PDK-1). Multiple studies

during the 1990s showed that PKCζ is a critical kinase for mitogenic signal transduction in a variety of cell types, including fibroblasts, brown adipocytes, endothelial cells, and oocytes (43). More recently, the importance of PKCζ for β-cell replication has also been elucidated. We and others have shown that growth factors such as GLP-1, parathyroid hormone-related protein, HGF, and nutrients such as glucose increase PKCζ phosphorylation and activity in insulinoma cells and rodent islets (44–46). Interestingly, activation of PKCζ using a constitutively active form of this kinase (CA-PKCζ) markedly increases β-cell proliferation in insulinoma and primary mouse β-cells in vitro, suggesting that PKCζ activation could be involved in growth factor-induced rodent β-cell proliferation (45,46). Indeed, small interfering RNA-based downregulation of PKCζ or the use of a dominant-negative form of PKCζ completely abolished growth factor-induced β-cell proliferation (45,46). Conversely, transgenic mice with expression of CA-PKCζ in β-cells display increased β-cell proliferation, size, and mass with a concomitant enhancement in insulin secretion and improved glucose tolerance (47). Downstream, activation of mTOR and upregulation of cyclin Ds and A are essential for PKCζ-mediated mitogenic effects in rodent β-cells (47). Collectively, these results indicate that PKCζ is a critical kinase for mitogenic signal transduction in rodent β-cells in vitro and in vivo.

PKCζ activation in rodent β-cells also leads to phosphorylation and inactivation of GSK3β (47), suggesting that PKCζ-mediated β-cell mitogenic effects might also be favored by GSK3β inactivation. GSK3β is one of the kinases known to phosphorylate D-cyclins and to regulate their degradation (48). Because PKCζ activation results in increased GSK3β phosphorylation/inactivation and increased expression of D-cyclins, it is possible that PKCζ increases the accumulation of D-cyclins in β-cells through inactivation of GSK3β. **Lactogen and Janus kinase–signal transducer and activation of transcription signaling.** In rodent β-cells, pregnancy-associated lactogens bind to the prolactin receptor, which then activates the Janus kinase JAK2, which results in phosphorylation/activation of the transcription factor signal transducer and activation of transcription 5 (STAT5) and its nuclear translocation. Phospho-STAT5 dimers bind to the promoter of the cyclin D2 gene and upregulate transcription of cyclin D2 mRNA, with resultant induction of β-cell proliferation. This pathway was demonstrated to exist in rodent β-cells (49). More recently, two reports have added depth and definition to this pathway. First, Kim and colleagues (50) has demonstrated that lactogenic signaling during pregnancy upregulates the transcription factor Bcl6, with resulting repression of the epigenetic histone methylase complex, trithorax component, menin. Through the trithorax complex, menin acts as a transcriptional repressor of the CDK inhibitors p18INK4 and p27cip, and their repression is therefore permissive for β-cell replication in pregnancy. Most recently, the German group (Kim et al.) (51) has demonstrated that lactogenic signaling during pregnancy also is associated with a dramatic, 1,000×, increase in serotonin production by β-cells, a reflection of the induction of β-cell tryptophan hydroxylases by lactogens. Unanswered questions still remain, such as which signaling pathways does 5HT2b activate in the β-cell? How exactly do these downstream signaling molecules affect the cell-cycle symphony?

Additional growth factor signaling pathways. In this brief *Perspectives in Diabetes*, only a few rodent β-cell signaling pathways can be described. It should be clear,

however, that multiple other signaling pathways linking growth factors to rodent β-cell replication exist. Examples include: a glucose–glut2–ChREBP–cMyc pathway (52); a glucose–AMP-activated protein kinase–LKB1–calcineurin–nuclear factor of activated T-cell pathway (27,28,53); an epidermal growth factor (EGF) ligand family (EGF, beta-cellulin, heparin-binding EGF, amphiregulin, and trefoil factor family 3)–EGF receptor–ras/raf–mitogen-activated protein kinase (MAPK)–cdk–cyclin pathway (54,55); a cAMP–cAMP-dependent protein kinase–CREB–cAMP response element modulator–cyclin A pathway (56,57); parathyroid hormone-related protein induction of proliferation (5); a leptin–IRS-2 pathway (58); a transforming growth factor-β activin family–SMAD pathway (59); sex hormone signaling pathways (60); cannabinoid receptors (CB1) that cross-talk with insulin receptors and IRS-2 (61) and calpains (62); and recently, a platelet-derived growth factor (PDGF) receptor linked to MAPK signaling pathway, driving the polycomb repressive complex family member Ezh2, with repression of p16INK4, thereby permitting activation of downstream cell-cycle molecules such as the pRb family pocket proteins and E2Fs (63).

CELL-CYCLE CONTROL OF PROLIFERATION IN THE RODENT β-CELL

This is an important and rapidly moving area. It is complex and well beyond the scope of a brief review, but detailed reviews are available (64–66). Briefly, downstream of every developmental program and nutrient- or growth factor-driven signaling pathway that is able to drive rodent β-cell proliferation, intracellular signaling pathways converge on the molecules that control the G₁/S checkpoint. This checkpoint is shown schematically in Fig. 2, and examples of interactions with upstream signaling pathways are shown in Fig. 3. Briefly, there are a number of cell cycle-activating molecules: the D-cyclins and their cognate cdk




FIG. 2. The rodent and human β-cell G₁/S molecule road map. These are the ultimate targets of upstream mitogenic signaling molecules. Those that activate cell-cycle progression (cyclins and cyclin-dependent kinases) are shown in green, and those that inhibit cell-cycle progression (the pocket proteins, INK4s, and the CIP/KIP families of cell-cycle inhibitors) are shown in red. The two wiring diagrams in rodents and human β-cells appear to be similar, with two exceptions (cyclin D2 and cdk6), indicated in black: 1) human islets have little cyclin D2, whereas this is abundant and critical in rodent β-cells; and 2) human islets contain abundant cdk6, a cdk that is absent in rodent β-cells. See text and references (64–66,71) for details. Modified from Cozar-Castellano et al. (66). (A high-quality color representation of this figure is available in the online issue.)




FIG. 3. Examples of reported upstream signaling pathways that activate cell-cycle progression in the rodent β -cell. This figure illustrates that there are many different ways in which a growth factor or nutrient can activate cell-cycle progression. Please note that the figure is oversimplified for clarity and is also incompletely defined. The Akt/PKB, PKC ζ , STAT5s, and β -catenin activate one or more cyclins and cdk proteins. MAPK has been reported to modulate Ezh2 to act via p16. CREB/cAMP response element modulator, Nkx6.1 and Pdx1 have been reported to act via the “late” cdk and cyclins, cdk1/2 and cyclins A/E. FoxM1 (91) has been reported to inhibit the Cip/Kip proteins, and menin, activate cMyc, and regulate Skp2 (92,93). PKC ζ activation in rodent β -cells leads to upregulation of cyclin Ds and A and diminished expression of p21. Modulation of one or more of these cell-cycle proteins is critical for phosphorylation and inactivation of pRb so that it can release the E2F transcription factors that are required for cell-cycle progression. Several additional β -cell mitogenic signaling pathways likely exist, including those activated by estrogen/progesterone receptors, and JUN kinase (depicted as “?”). Green indicates proteins that promote proliferation, whereas red indicates proteins that inhibit proliferation. (A high-quality color representation of this figure is available in the online issue.)

and the E/A-cyclins and their cognate cdks, cdk1 and -2. Overexpression of all of these in various combinations is able to drive rodent β -cell proliferation, either when delivered adenovirally (67) or transgenically, and in some cases (but not all), disruption of their genes leads to β -cell hypoplasia, hypoinsulinemia, and diabetes (64–66). Thus, these cell-cycle activators are key targets of upstream pathways, and they have been shown to be regulated by these signaling pathways, growth factors (as described above), and glucose and glucokinase activators (68).

These cell-cycle activators are balanced by a series of cell-cycle inhibitors, which include the so-called “pocket proteins” (pRb, p107, and p130), the INK4 family (p15, p16, p18, and p19), the CIP/KIP family (p21, p27, and p57), menin, and p53. The details of their actions and interactions with the cyclins and cdks are too complex for a brief discussion, but detailed reviews are available. The key points in the current context are that they, too, are essential regulators of β -cell cycle progression (e.g., p21 and p27 are regulated by mitogens and p16 and p18 by free fatty acids), and genetic disruption of the genes encoding some of these molecules leads to β -cell hyperplasia and hyperfunction (69,70).

In this context, it is important to emphasize that these G_1/S molecules have short half-lives and frequently, if not most often, are regulated at the level of protein stability. This is important because changes seen at the mRNA level frequently correlate poorly with those observed at the protein level.

Thus, we know an enormous amount about cell-cycle control in the rodent β -cell and how key signaling pathways regulate these molecules.

CELL-CYCLE CONTROL IN THE HUMAN β -CELL

As in the rodent β -cell, the G_1/S molecules controlling human β -cell proliferation have also been studied, and

much is now known. For example, we have a relatively complete understanding of which of the ~ 30 G_1/S molecules are present in the human islet, and they can be arranged in a working wiring diagram or road map, which looks very similar to the rodent version in Fig. 2 (71). In addition, we know that adenoviral overexpression of certain cell-cycle regulatory molecules (e.g., cMyc, the cdks, or the cyclins D or E) in the human β -cell activates proliferation robustly. For example, with adenoviral overexpression of cell-cycle molecules, as many as 10–15% of adult human β -cells are able to replicate as assessed using Ki-67 immunohistochemistry or bromodeoxyuridine incorporation (71–74).

Although the human β -cell G_1/S road map is similar to that in the rodent β -cell, there are two principal differences, indicated by the black numbers in Fig. 2. First, cdk6 is absent in rodent β -cells but abundant in human β -cells (71). This is relevant because genetic loss of cdk4 in mice leads to β -cell hypoplasia and diabetes, presumably because there is no cdk6 to compensate for this loss. Second, although all three D-cyclins are present in the mouse β -cell, genetic loss of cyclin D2 (but not cyclins D1 or D3) in mice leads to β -cell hypoplasia and diabetes, indicating that this is the key D-cyclin in the rodent β -cell (75,76). In contrast, human islets contain little or no cyclin D2 (71), suggesting, paradoxically, either that cyclin D2 is irrelevant in the human β -cell or that it is absolutely essential, with its paucity being precisely the reason that human β -cells do not replicate.

Failure to signal from cell surface to cell-cycle machinery. Most importantly in the current context, because adult human β -cells do not replicate in response to the long list of growth factors, nutrients, and maneuvers that induce rodent β -cells to replicate, but clearly can replicate when cyclins and cdks are overexpressed (71–73), it is clear that failure or inadequacy of the cell-cycle

machinery in human β-cells is not the reason they do not replicate; the machinery is there and waiting to be activated. Thus, the likely missing link in adult human β-cell replication is not failure to express key cell-cycle molecules, but rather a failure to activate them in response to what would appear to be appropriate upstream signals. More specifically, the blockade(s) would appear to be somewhere among the levels of the upstream growth factors, their receptors, signaling pathways that should, but do not, alter these cell-cycle molecules.

THERE IS NO HUMAN β-CELL RECEPTOR–NUTRIENT–SIGNALING–CELL-CYCLE PATHWAY ROAD MAP

If human β-cells possess the requisite G₁/S molecules to drive β-cell replication, and their upregulation can drive human β-cell replication, it is then axiomatic that signaling events that should be reaching the cell-cycle machinery are not. It therefore would be particularly useful to have a human β-cell signaling road map that describes these intracellular signaling pathways, with their upstream ligands and receptors and downstream cell-cycle targets. Unfortunately, in contrast to the rich and complex road map for growth factor and nutrient induction of rodent β-cell replication, no such road map exists for the human β-cell: we remain very much in the dark regarding receptors, nutrient transporters/sensors, their downstream signaling pathways, and their putative connections to the ultimate downstream cell-cycle regulatory molecules. Simply said, the human β-cell signaling road map is almost a blank slate, a tabula rasa, as shown in the light gray lines and text in the upper portion of Fig. 4, which should be contrasted to their counterparts in Fig. 1. The following sections briefly summarize the little that we do know.

IRS-PI3K-Akt signaling. Human islet cells express insulin and IGF-I receptors and components of these signaling pathways (5,77). In functional terms, several studies support the concept of a direct insulin action in the β-cell

that promotes a positive-feedback effect in vivo in healthy humans (78) that is blunted in patients with T2DM (79,80). Ex vivo examination of human islets and pancreas sections from T2DM patients (77,81) supports a role for the insulin-signaling network in the regulation of cell-cycle proteins. Although an increase in β-cell volume has been reported in humans with obesity (82), it is unclear whether this occurs as a compensatory response to insulin resistance, as occurs in animal models, or is genetically predetermined. Additional studies that directly address this possibility are warranted.

mTORC1 and regulation of human β-cell proliferation. The expression of some mTOR signaling components has been demonstrated in human islets (83) exemplified by its induction by glucose, amino acids, and insulin (84). Most of our understanding of mTOR signaling in human islets is derived from studies using rapamycin derivatives as immunosuppressants or as treatment of patients with insulinomas and other neuroendocrine tumors. Rapamycin treatment has been shown to inhibit human β-cell proliferation in vitro (41). Moreover, *TSC2* and *PTEN* expression is decreased in insulinomas and pancreatic endocrine tumors, suggesting that activation of mTORC1 and Akt signaling plays a role in the proliferative changes observed in these tumors (85). However, insulinomas are rare in patients with tuberous sclerosis. In contrast, mTORC1 inhibition by everolimus (a rapamycin analog) improves glycemic control in patients with insulinoma and prolongs progression-free survival in patients with pancreatic neuroendocrine tumors (86,87). The extent to which reduced β-cell mass or inhibition of insulin secretion contributes to the responses to mTORC1 inhibition is unclear, but, based on the current evidence, it is likely that inhibition of β-cell proliferation plays a major role.

PKCζ and GSK3β signaling in the human β-cell. Pharmacological inhibition of GSK3β has been shown to enhance (approximately fourfold) glucose-mediated human




FIG. 4. The rudimentary human β-cell mitogenic signaling road map. Contrast this figure to Fig. 1. The gray lines are molecules and pathways that are known to exist in rodents but are unstudied in human β-cells. The human β-cell signaling road map is underdeveloped: Although the human G₁/S molecules are reasonably well-characterized in the human β-cell (66), only a handful of growth factor receptors (e.g., IR, IGF-1R, and c-Met) and signaling molecules (IRS-1, IRS-2, PI3K, Akt, PKCζ, and GSK3β) are known to be present in human β-cell, and the majority of the proteins involved in signaling have not been studied.

β -cell proliferation (although from very low to low basal rates) (41), and adenoviral transduction of human islets with CA-PKC ζ in vitro enhances (approximately fourfold) human β -cell proliferation (45). However, whether PKC ζ -induced human β -cell proliferation is mediated or potentiated by GSK3 β inactivation is unknown.

In summary, it is important to emphasize that at present, although many examples exist in rodent β -cells, we do not have a single example of a complete pathway in the human β -cell that links a growth factor or nutrient, via a cell-surface receptor through a complete signaling pathway, to the downstream cell-cycle machinery that translates to proliferation. In this regard, the recent report of a PDGF-PDGF receptor-MAPK-Ezh2-p16 pathway (63) is exciting and comes the closest to filling this void.

WHY WE NEED A HUMAN β -CELL MITOGENIC SIGNALING PATHWAY ROAD MAP

Comparing Figs. 1 and 4 makes it clear that informed efforts to drive therapeutic human β -cell proliferation are severely hampered by the essentially complete lack of a human β -cell road map. Further, the fact that direct cell-cycle activation by cyclin/cdk overexpression can markedly activate human β -cell proliferation places at least one key obstacle to human β -cell proliferation within these upstream signaling pathways, about which we know so little. As noted below, it would be informative to investigate the upstream signaling pathways and identify proteins that link the cell-surface receptors with key molecules in the cell-cycle machinery in human β -cells.

Examples of key questions about which we have no answers are: 1) do the gray molecules and lines in Fig. 4 even exist in adult human β -cells?; 2) are there key signaling pathways in human islets that we have completely overlooked? [e.g., erythropoietin, insulin, serotonin, and osteocalcin have all been proposed as physiologic drivers of rodent β -cell replication (51,88,89), but have not been comprehensively tested in human β -cells]; 3) do adult human β -cells require engagement of receptors or nutrients distinct from those on rodent β -cells; 4) what are the intracellular signaling networks and cell-cycle targets regulated by the kinases in Fig. 4 that *are* present in human β -cells?; 5) are these kinases activated by growth factors and nutrients, and, if not, what is preventing them from being activated?; 6) can coordinate activation of combinations of pathways synergize to enhance proliferation (e.g., if overexpression of PKC ζ and inhibition of GSK3 β can increase human β -cell replication from 0.2 to 1.0%, would coordinate activation of multiple pathways further increase replication?); 7) are the cell-cycle inhibitors that are so abundant in human β -cells restraining proliferation, and how are they regulated?; 8) are key cell-cycle regulatory elements epigenetically regulated (in this study, for example, the epigenetic methylases and demethylases *menin*, *Ezh2*, and *Bmi1* have all been shown to participate in restraining rodent β -cell replication?); 9) in this era of high-throughput screening, which are the optimal small-molecule targets in the human β -cell to drive proliferation?; and 10) why and how do β -cells in young humans proliferate at a higher rate compared with those from older individuals?

The answers to these critical questions are simply that we know very little: we have no road map from which to hypothesize, model, and integrate data from multiple systems. We believe that obtaining the information required

to create such a road map is essential. Without this information, we are driving at night without headlights, without a road map, and without global positioning system navigation. It is time to develop such a high-content signaling road map that connects the cell surface to cell-cycle machinery in the human β -cell.

ACKNOWLEDGMENTS

This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)/National Institutes of Health (NIH) grants R01-DK-67536 and R21-RR-24905 and Juvenile Diabetes Research Foundation (JDRF) Grant 17-2011-644 (to R.N.K.), NIDDK/NIH grants R01-DK-73716 and R01-DK-84236, JDRF Grant 46-2010-758, and Career Development Award 7-06-CD-02 from the American Diabetes Association (ADA) (to E.-B.M.), NIDDK/NIH grants R01-DK-77096 and R01-DK-67351 and Research Award 1-10-BS-59 from the ADA (to A.G.O.), NIDDK and the Beta Cell Biology Consortium through NIH grants U01-DK-089538 and R01-DK-55023, and JDRF grants 1-2008-39 and 34-2008-630 (to A.F.S.).

No potential conflicts of interest relevant to this article were reported.

R.N.K., E.-B.M., A.G.O., and A.F.S. wrote the manuscript, reviewed and edited the manuscript, and contributed to the discussion. R.N.K., E.-B.M., A.G.O., and A.F.S. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

The authors thank the innumerable authors who have contributed to the field of β -cell intracellular signaling and apologize for not being able to discuss and/or cite all of the important contributions because of editorial limitations on the text and numbers of references allowed.

REFERENCES

- Rankin MM, Kushner JA. Adaptive beta-cell proliferation is severely restricted with advanced age. *Diabetes* 2009;58:1365-1372
- Kassem SA, Ariel I, Thornton PS, Scheimberg I, Glaser B. Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. *Diabetes* 2000;49:1325-1333
- Meier JJ, Butler AE, Saisho Y, et al. Beta-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. *Diabetes* 2008;57:1584-1594
- Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. *Nature* 2001;414:799-806
- Assmann A, Hinault C, Kulkarni RN. Growth factor control of pancreatic islet regeneration and function. *Pediatr Diabetes* 2009;10:14-32
- Kulkarni RN, Brünig JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in type 2 diabetes. *Cell* 1999;96:329-339
- Withers DJ, Gutierrez JS, Towery H, et al. Disruption of IRS-2 causes type 2 diabetes in mice. *Nature* 1998;391:900-904
- Ueki K, Okada T, Hu J, et al. Total insulin and IGF-I resistance in pancreatic beta cells causes overt diabetes. *Nat Genet* 2006;38:583-588
- Okada T, Liew CW, Hu J, et al. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. *Proc Natl Acad Sci USA* 2007;104:8977-8982
- Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. *Mol Cell* 2000;6:87-97
- Araki E, Lipes MA, Patti ME, et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. *Nature* 1994;372:186-190
- Kulkarni RN, Roper MG, Dahlgren G, et al. Islet secretory defect in insulin receptor substrate 1 null mice is linked with reduced calcium signaling and expression of sarco(endo)plasmic reticulum Ca²⁺-ATPase (SERCA)-2b and -3. *Diabetes* 2004;53:1517-1525

13. Hennige AM, Ozcan U, Okada T, et al. Alterations in growth and apoptosis of insulin receptor substrate-1-deficient beta-cells. *Am J Physiol Endocrinol Metab* 2005;289:E337–E346
14. Kubota N, Tobe K, Terauchi Y, et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory β-cell hyperplasia. *Diabetes* 2000;49:1880–1889
15. Choudhury AI, Heffron H, Smith MA, et al. The role of insulin receptor substrate 2 in hypothalamic and beta cell function. *J Clin Invest* 2005;115:940–950
16. Park S, Dong X, Fisher TL, et al. Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. *J Biol Chem* 2006;281:1159–1168
17. Garofalo RS, Orena SJ, Rafidi K, et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. *J Clin Invest* 2003;112:197–208
18. Cho H, Mu J, Kim JK, et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). *Science* 2001;292:1728–1731
19. Bernal-Mizrachi E, Fatrai S, Johnson JD, et al. Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cells. *J Clin Invest* 2004;114:928–936
20. Tuttle RL, Gill NS, Pugh W, et al. Regulation of pancreatic beta-cell growth and survival by the serine/threonine protein kinase Akt1/PKBalpha. *Nat Med* 2001;7:1133–1137
21. Bernal-Mizrachi E, Wen W, Stahlhut S, Welling CM, Permutt MA. Islet beta cell expression of constitutively active Akt1/PKB alpha induces striking hypertrophy, hyperplasia, and hyperinsulinemia. *J Clin Invest* 2001;108:1631–1638
22. Fatrai S, Elghazi L, Balcazar N, et al. Akt induces beta-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. *Diabetes* 2006;55:318–325
23. Kaneko K, Ueki K, Takahashi N, et al. Class IA phosphatidylinositol 3-kinase in pancreatic β cells controls insulin secretion by multiple mechanisms. *Cell Metab* 2010;12:619–632
24. Liu Z, Tanabe K, Bernal-Mizrachi E, Permutt MA. Mice with beta cell overexpression of glycogen synthase kinase-3beta have reduced beta cell mass and proliferation. *Diabetologia* 2008;51:623–631
25. Liu Y, Tanabe K, Baronnier D, et al. Conditional ablation of Gsk-3β in islet beta cells results in expanded mass and resistance to fat feeding-induced diabetes in mice. *Diabetologia* 2010;53:2600–2610
26. Huang W, Chang HY, Fei T, Wu H, Chen YG. GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN. *Oncogene* 2007;26:2471–2482
27. Fu A, Ng AC, Depatie C, et al. Loss of Lkb1 in adult beta cells increases beta cell mass and enhances glucose tolerance in mice. *Cell Metab* 2009;10:285–295
28. Granot Z, Swisa A, Magenheim J, et al. LKB1 regulates pancreatic beta cell size, polarity, and function. *Cell Metab* 2009;10:296–308
29. Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. *J Biol Chem* 2010;285:14071–14077
30. Rachdi L, Balcazar N, Osorio-Duque F, et al. Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner. *Proc Natl Acad Sci USA* 2008;105:9250–9255
31. Shigeyama Y, Kobayashi T, Kido Y, et al. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. *Mol Cell Biol* 2008;28:2971–2979
32. Mori H, Inoki K, Opland D, et al. Critical roles for the TSC-mTOR pathway in β-cell function. *Am J Physiol Endocrinol Metab* 2009;297:E1013–E1022
33. Hamada S, Hara K, Hamada T, et al. Upregulation of the mammalian target of rapamycin complex 1 pathway by Ras homolog enriched in brain in pancreatic beta-cells leads to increased beta-cell mass and prevention of hyperglycemia. *Diabetes* 2009;58:1321–1332
34. Alliouachene S, Tuttle RL, Boumard S, et al. Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation. *J Clin Invest* 2008;118:3629–3638
35. Elghazi L, Balcazar N, Blandino-Rosano M, et al. Decreased IRS signaling impairs beta-cell cycle progression and survival in transgenic mice overexpressing S6K in beta-cells. *Diabetes* 2010;59:2390–2399
36. Balcazar N, Sathyamurthy A, Elghazi L, et al. mTORC1 activation regulates beta-cell mass and proliferation by modulation of cyclin D2 synthesis and stability. *J Biol Chem* 2009;284:7832–7842
37. Zahr E, Molano RD, Pileggi A, et al. Rapamycin impairs in vivo proliferation of islet beta-cells. *Transplantation* 2007;84:1576–1583
38. Niclauss N, Bosco D, Morel P, Giovannoni L, Berney T, Parnaud G. Rapamycin impairs proliferation of transplanted islet β cells. *Transplantation* 2011;91:714–722
39. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. *Diabetes* 2008;57:945–957
40. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. *J Clin Invest* 2007;117:2553–2561
41. Liu H, Remedi MS, Pappan KL, et al. Glycogen synthase kinase-3 and mammalian target of rapamycin pathways contribute to DNA synthesis, cell cycle progression, and proliferation in human islets. *Diabetes* 2009;58:663–672
42. Gu Y, Lindner J, Kumar A, Yuan W, Magnuson MA. Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size. *Diabetes* 2011;60:827–837
43. Hirai T, Chida K. Protein kinase Czeta (PKCzeta): activation mechanisms and cellular functions. *J Biochem* 2003;133:1–7
44. Buteau J, Foisy S, Rhodes CJ, Carpenter L, Biden TJ, Prentki M. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. *Diabetes* 2001;50:2237–2243
45. Vasavada RC, Wang L, Fujinaka Y, et al. Protein kinase C-zeta activation markedly enhances beta-cell proliferation: an essential role in growth factor mediated beta-cell mitogenesis. *Diabetes* 2007;56:2732–2743
46. Miele C, Raciti GA, Cassese A, et al. PED/PEA-15 regulates glucose-induced insulin secretion by restraining potassium channel expression in pancreatic beta-cells. *Diabetes* 2007;56:622–633
47. Velazquez-Garcia S, Valle S, Rosa TC, et al. Activation of protein kinase C-ζ in pancreatic β-cells in vivo improves glucose tolerance and induces β-cell expansion via mTOR activation. *Diabetes* 2011;60:2546–2559
48. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. *Genes Dev* 1998;12:3499–3511
49. Friedrichsen BN, Richter HE, Hansen JA, et al. Signal transducer and activator of transcription 5 activation is sufficient to drive transcriptional induction of cyclin D2 gene and proliferation of rat pancreatic beta-cells. *Mol Endocrinol* 2003;17:945–958
50. Karnik SK, Chen H, McLean GW, et al. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. *Science* 2007;318:806–809
51. Kim H, Toyofuku Y, Lynn FC, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. *Nat Med* 2010;16:804–808
52. Metukuri MR, Zhang P, Basantani MK, et al. ChREBP mediates glucose-stimulated pancreatic beta cell proliferation. *Diabetes*. 14 May 2012 [Epub ahead of print]
53. Heit JJ, Apelqvist AA, Gu X, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. *Nature* 2006;443:345–349
54. Hakonen E, Ustinov J, Mathijs I, et al. Epidermal growth factor (EGF)-receptor signalling is needed for murine beta cell mass expansion in response to high-fat diet and pregnancy but not after pancreatic duct ligation. *Diabetologia* 2011;54:1735–1743
55. Fueger PT, Schisler JC, Lu D, et al. Trefoil factor 3 stimulates human and rodent pancreatic islet beta-cell replication with retention of function. *Mol Endocrinol* 2008;22:1251–1259
56. Song WJ, Schreiber WE, Zhong E, et al. Exendin-4 stimulation of cyclin A2 in beta-cell proliferation. *Diabetes* 2008;57:2371–2381
57. Schisler JC, Fueger PT, Babu DA, et al. Stimulation of human and rat islet beta-cell proliferation with retention of function by the homeodomain transcription factor Nkx6.1. *Mol Cell Biol* 2008;28:3465–3476
58. Morioka T, Asilmaz E, Hu J, et al. Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. *J Clin Invest* 2007;117:2860–2868
59. Brown ML, Schneyer AL. Emerging roles for the TGFβ family in pancreatic beta-cell homeostasis. *Trends Endocrinol Metab* 2010;21:441–448
60. Tiano JP, Mauvais-Jarvis F. Importance of oestrogen receptors to preserve functional beta-cell mass in diabetes. *Nat Rev Endocrinol* 2012;8:342–351
61. Kim W, Lao Q, Shin YK, et al. Cannabinoids induce pancreatic β-cell death by directly inhibiting insulin receptor activation. *Sci Signal* 2012;5:ra23
62. Sreenan SK, Zhou YP, Otani K, et al. Calpains play a role in insulin secretion and action. *Diabetes* 2001;50:2013–2020
63. Chen H, Gu X, Liu Y, et al. PDGF signalling controls age-dependent proliferation in pancreatic β-cells. *Nature* 2011;478:349–355
64. Heit JJ, Karnik SK, Kim SK. Intrinsic regulators of pancreatic beta-cell proliferation. *Annu Rev Cell Dev Biol* 2006;22:311–338
65. Cozar-Castellano I, Fiaschi-Taesch N, Bigatel TA, et al. Molecular control of cell cycle progression in the pancreatic beta-cell. *Endocr Rev* 2006;27:356–370

66. Cozar-Castellano I, Weinstock M, Haught M, Velázquez-García S, Sipula D, Stewart AF. Evaluation of beta-cell replication in mice transgenic for hepatocyte growth factor and placental lactogen: comprehensive characterization of the G1/S regulatory proteins reveals unique involvement of p21cip. *Diabetes* 2006;55:70–77
67. Cozar-Castellano I, Harb G, Selk K, et al. Lessons from the first comprehensive molecular characterization of cell cycle control in rodent insulinoma cell lines. *Diabetes* 2008;57:3056–3068
68. Porat S, Weinberg-Corem N, Tornovsky-Babaey S, et al. Control of pancreatic β cell regeneration by glucose metabolism. *Cell Metab* 2011;13:440–449
69. Harb G, Vasavada RC, Cobrinik D, Stewart AF. The retinoblastoma protein and its homolog p130 regulate the G1/S transition in pancreatic beta-cells. *Diabetes* 2009;58:1852–1862
70. Krishnamurthy J, Ramsey MR, Ligon KL, et al. p16INK4a induces an age-dependent decline in islet regenerative potential. *Nature* 2006;443:453–457
71. Fiaschi-Taesch N, Bigatel TA, Sicari B, et al. Survey of the human pancreatic beta-cell G1/S proteome reveals a potential therapeutic role for cdk-6 and cyclin D1 in enhancing human beta-cell replication and function in vivo. *Diabetes* 2009;58:882–893
72. Karslioglu E, Kleinberger JW, Salim FG, et al. cMyc is a principal upstream driver of beta-cell proliferation in rat insulinoma cell lines and is an effective mediator of human beta-cell replication. *Mol Endocrinol* 2011;25:1760–1772
73. Guthalu Kondegowda N, Joshi-Gokhale S, Harb G, et al. Parathyroid hormone-related protein enhances human β -cell proliferation and function with associated induction of cyclin-dependent kinase 2 and cyclin E expression. *Diabetes* 2010;59:3131–3138
74. Fiaschi-Taesch NM, Salim F, Kleinberger J, et al. Induction of human beta-cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6. *Diabetes* 2010;59:1926–1936
75. Kushner JA, Ciemerych MA, Sicinska E, et al. Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. *Mol Cell Biol* 2005;25:3752–3762
76. Georgia S, Hinault C, Kawamori D, et al. Cyclin D2 is essential for the compensatory beta-cell hyperplastic response to insulin resistance in rodents. *Diabetes* 2010;59:987–996
77. Gunton JE, Kulkarni RN, Yim S, et al. Loss of ARNT/HIF1 β mediates altered gene expression and pancreatic-islet dysfunction in human type 2 diabetes. *Cell* 2005;122:337–349
78. Lopez X, Cypess A, Manning R, O'Shea S, Kulkarni RN, Goldfine AB. Exogenous insulin enhances glucose-stimulated insulin response in healthy humans independent of changes in free fatty acids. *J Clin Endocrinol Metab* 2011;96:3811–3821
79. Halperin F, Lopez X, Manning R, Kahn CR, Kulkarni RN, Goldfine A. Insulin augmentation of glucose-stimulated insulin secretion is impaired in insulin-resistant humans. 2012;61:301–309
80. Mari A, Tura A, Natali A, et al.; RISC Investigators. Influence of hyperinsulinemia and insulin resistance on in vivo β -cell function: their role in human β -cell dysfunction. *Diabetes* 2011;60:3141–3147
81. Folli F, Okada T, Perego C, et al. Altered insulin receptor signalling and β -cell cycle dynamics in type 2 diabetes mellitus. *PLoS ONE* 2011;6:e28050
82. Klöppel G, Löhr M, Habich K, Oberholzer M, Heitz PU. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. *Surv Synth Pathol Res* 1985;4:110–125
83. McDaniel ML, Marshall CA, Pappan KL, Kwon G. Metabolic and autocrine regulation of the mammalian target of rapamycin by pancreatic beta-cells. *Diabetes* 2002;51:2877–2885
84. Kwon G, Marshall CA, Pappan KL, Remedi MS, McDaniel ML. Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. *Diabetes* 2004;53(Suppl. 3):S225–S232
85. Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. *J Clin Oncol* 2010;28:245–255
86. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. *N Engl J Med* 2009;360:195–197
87. Yao JC, Shah MH, Ito T, et al.; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:514–523
88. Choi D, Schroer SA, Lu SY, et al. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. *J Exp Med* 2010;207:2831–2842
89. Ferron M, Wei J, Yoshizawa T, et al. Insulin signaling in osteoblasts integrates bone remodeling and energy metabolism. *Cell* 2010;142:296–308
90. Kitamura T, Nakae J, Kitamura Y, et al. The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. *J Clin Invest* 2002;110:1839–1847
91. Zhang H, Ackermann AM, Gusarova GA, et al. The FoxM1 transcription factor is required to maintain pancreatic beta-cell mass. *Mol Endocrinol* 2006;20:1853–1866
92. Wang IC, Chen YJ, Hughes D, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. *Mol Cell Biol* 2005;25:10875–10894
93. Zhong L, Georgia S, Tschen SI, Nakayama K, Nakayama K, Bhushan A. Essential role of Skp2-mediated p27 degradation in growth and adaptive expansion of pancreatic beta cells. *J Clin Invest* 2007;117:2869–2876